Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 17:16:17562848231163118.
doi: 10.1177/17562848231163118. eCollection 2023.

Can we change the natural course of inflammatory bowel disease?

Catherine Le Berre  1 , Silvio Danese  2 , Laurent Peyrin-Biroulet  3
Affiliations
Review

Can we change the natural course of inflammatory bowel disease?

Catherine Le Berre et al. Therap Adv Gastroenterol. .

Abstract

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are lifelong diseases characterized by chronic inflammation of the gastrointestinal tract leading to its progressive and irreversible destruction. Whether early initiation of IBD-specific therapy impacts the long-term course of the disease remains unclear and has to be further explored in prospective disease-modification trials. Historically, surgery and hospitalization rates have been the surrogate markers to measure disease progression in IBD, providing an overview of the effectiveness of medical therapies. However, neither surgery nor hospitalization necessarily reflects a fail in therapeutic medical management, and many confounding factors make them biased outcomes. The Selecting Endpoints for Disease-Modification Trials consensus has defined the disease-modification endpoints required for these trials, including the impact of the disease on patient's life (health-related quality of life, disability, and fecal incontinence), the mid-term disease complications (bowel damage in CD, IBD-related surgery and hospitalizations, disease extension in UC, extra-intestinal manifestations, permanent stoma, short bowel syndrome), and the development of dysplasia/cancer and mortality in the long term. Most available data in the literature regarding the impact of current therapies on disease progression focused on anti-tumor necrosis factor agents and are based on retrospective or post-hoc studies. Thus, prospective disease-modification trials are pressingly required to explore the effectiveness of early intensified treatment in patients with severe disease or at risk for disease progression.

Keywords: Crohn’s disease; complications; disease modification; disease progression; inflammatory bowel disease; treat-to-target; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

CLB has served as a consultant for Abbvie, Janssen and Gilead, and reports receiving payment for lectures from AbbVie, Celltrion, Ferring, Fresenius Kabi, Galapagos, Janssen, MSD, Pfizer and Takeda. SD has served as a speaker, consultant and advisory board member for Schering-Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, Theravance. LPB has served as a speaker, consultant and advisory board member for Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, HAC-Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, Theravance.

Figures

Figure 1.
Figure 1.
Schematic representation of the concept of ‘therapeutic window of opportunity’ in IBD. IBD, inflammatory bowel disease.
Figure 2.
Figure 2.
Summary of the process leading to the SPIRIT consensus. IBD, inflammatory bowel disease; IOIBD, International Organization for the Study of Inflammatory Bowel Diseases; SPIRIT, Selecting Endpoints for Disease-Modification Trials.
See this image and copyright information in PMC

References

    1. Ng SC, Shi HY, Hamidi N, et al.. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769–2778. - PubMed
    1. Pariente B, Mary J-Y, Danese S, et al.. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology 2015; 148: 52–63.e3. - PubMed
    1. Peyrin-Biroulet L, Loftus EV, Colombel J-F, et al.. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289–297. - PubMed
    1. Harbord M, Eliakim R, Bettenworth D, et al.. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11: 769–784. - PubMed
    1. Torres J, Bonovas S, Doherty G, et al.. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020; 14: 4–22. - PubMed

LinkOut - more resources